You are here: Industry Insights > ENHANZE

News List

Collaboration to develop ultra-long acting medicines for HIV europeanpharmaceuticalreview
June 23, 2021
ViiV Healthcare is licencing Halozyme’s Enhanze® drug delivery technology to help develop ultra-long acting versions of its long-acting HIV pipeline products.
Pertuzumab, Trastuzumab Combination with ENHANZE Drug Delivery Meets Primary Endpoint americanpharmaceuticalreview
September 17, 2019
Halozyme announced the global phase III FeDeriCa study conducted by Genentech, a member of the Roche Group, met its primary endpoint.
Argenx to leverage Halozyme’s subcutaneous drug delivery technology pharmaceutical-technology
February 19, 2019
Dutch biotechnology company Argenx has signed a global collaboration and licence agreement to leverage US-based Halozyme Therapeutics’ drug delivery technology ENHANZE....
Halozyme licenses $25M drug delivery technology to Roche biospectrumasia
November 26, 2018
Halozyme has out-licensed its ENHANZE drug delivery technology to Roche for the exclusive development of a new undisclosed drug target with an option to add two more within four years.
Bristol-Myers Squibb collaborates with ENHANZE technology biospectrumasia
September 18, 2017
Under the agreement, Halozyme to receive $105 million upfront payment, plus future milestones and royalties